Get the Stockscreener App
6.25
11.81%
0.66
After Hours:
6.20
-0.05
-0.80%
Sionna Therapeutics Inc stock is traded at $6.25, with a volume of 1.97M.
It is up +11.81% in the last 24 hours and down -86.32% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$5.59
Open:
$5.6
24h Volume:
1.97M
Relative Volume:
1.20
Market Cap:
$282.58M
Revenue:
-
Net Income/Loss:
$-85.57M
P/E Ratio:
-3.261
EPS:
-1.9166
Net Cash Flow:
$-72.14M
1W Performance:
+5.22%
1M Performance:
-86.32%
6M Performance:
-83.57%
1Y Performance:
-74.02%
1-Day Range:
$5.58
$6.30
1-Week Range:
$5.21
$6.30
52-Week Range:
$4.01
$54.97
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
6.25 | 249.57M | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
552.85 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
833.56 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,019.49 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
158.83 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.38 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Citizens | Mkt Outperform |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Connect - ACCESS Newswire
Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sionna (SION) Earnings Reading: Profit Per Share Clears Its Benchmark in the Latest Reading; Price Move - vinanet.vn
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - Yahoo Finance
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
2026-08-20 | Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:SION | Press Release - Stockhouse
Sionna (SION) Quarterly Figures: The Bottom-Line Figure Beats Its Comparison in the Current Update; Trading Response: The Share Price Adds 5.22% for the Current SessionTangible Book Value - vinanet.vn
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sionna shares plunge 92% after Phase 2a trial o... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sionna Therapeutics (SION) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - WBOC TV
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - FinancialContent
Sionna Therapeutics, Inc. Common Stock (NASDAQ: SION) Stock Price, News & Analysis - Kalkine
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information - Business Wire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Sionna Therapeutics (SION) - GlobeNewswire
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? - Stocktwits
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
SION INVESTOR ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - The Daily Tribune News
symbol__ Stock Quote Price and Forecast - CNN
Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION) - Business Wire
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - PR Newswire
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep? - Yahoo Finance
Sionna Therapeutics (SION) Is Down 86.8% After Halting SION-719 And Refocusing Its CF Pipeline – Has The Bull Case Changed? - Yahoo Finance
SION ALERT: Investigation Launched into Sionna Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - PR Newswire
Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) - Morningstar
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sionna's SION-719 Failure Changes Everything (Rating Downgrade) - Seeking Alpha
Sionna Therapeutics (NASDAQ:SION) Downgraded to Hold Rating by Lifesci Capital - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Lowered to Hold Rating by JonesTrading - MarketBeat
Sionna Therapeutics (SION) Stock Still Looks Cheap After The 90% Fall - Yahoo Finance
SIONNA THERAPEUTICS, INC. : WEDBUSH CUTS TO NEUTRAL FROM OUTPERFORM; CUTS TARGET PRICE TO $5 FROM $53 - webull.com
SION Q2 2026 Earnings: Narrower $0.66 Loss Drives 16.4% Jump in SharesFinancial Summary - vinanet.vn
One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses - finance.yahoo.com
SION Stock Slides, Then Snaps Back As Traders Eye Volatility - StocksToTrade
Sionna Therapeutics, Inc. (SION) Shares Plummet Following Clinical Trial Results—Johnson Fistel Investigates - GlobeNewswire
Sionna Therapeutics stock falls 92% after SION-719 trial failure - qz.com
BTIG Downgrades Sionna Therapeutics to Neutral From Buy - marketscreener.com
Sionna Therapeutics (SION) Halts Lead Cystic Fibrosis Drug After Phase 2 Failure - Yahoo Finance
Accendra Health, Celestica, Sionna Therapeutics - TradingView
SIONNA THERAPEUTICS, INC. : BTIG CUTS TO NEUTRAL FROM BUY - Bitget
Sionna Therapeutics, Inc.Common Stock (SION) Stock Price, News, Quote & History - FinancialContent
SIONNA THERAPEUTICS, INC. : JONESTRADING CUTS TO HOLD RATING - Bitget
Sionna Halts SION-719 After Phase 2a Miss, Eyes SION-451 Combination Path - TradingView
Sionna shares plummet after cystic fibrosis clinical trial failure - mugglehead.com
Sionna Therapeutics (NASDAQ:SION) Sets New 1-Year Low After Analyst Downgrade - MarketBeat
Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low -- Barrons.com - Moomoo
Health Care Up on Rotation to Less Inflation Sensitive SectorsHealth Care Roundup - Moomoo
Sionna Therapeutics: Hold Rating Maintained as Disappointing CF Data Drive Price Target Cut from $60 to $6 - TipRanks
Sionna Therapeutics Inc Stock (SION) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
6.11 |
10,250 |
62,628 |
10,250 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Sale |
43.60 |
10,250 |
446,862 |
0 |
0.07%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):